Share This Link

A heart rate of 105/min is slightly elevated, but it does not require immediate intervention unless the client is symptomatic or has other concerning signs.

Increased blood pressure is a common effect of dopamine administration and does not necessarily require urgent intervention unless it becomes critically high or is associated with other adverse symptoms.

Occasional PVCs can occur during dopamine infusion and can be monitored unless they become frequent or symptomatic; they typically do not require immediate intervention.

Delaying the incident report until the end of the current shift can compromise the timely documentation of the error and any necessary interventions that may arise.

While it's important to notify risk management, the priority should be to document the incident immediately after assessing the client to ensure a complete record of the error.

Informing the previous nurse is necessary for communication, but it should not delay the completion of the incident report, which is crucial for tracking errors and improving safety protocols.

Monitoring alanine aminotransferase is important for liver function, but it is not the priority for a client on captopril.

Thyroid-stimulating hormone is not directly impacted by captopril and is not the priority lab value to monitor in this context.

While magnesium levels are important to monitor, they are not specifically related to captopril therapy as potassium levels are.

The nursing supervisor does not usually unlock the medication drawer; this is typically done by the nurse in charge or the individual administering the medications.

While it is important to limit the number of controlled substances, the medication drawer is usually stocked in a manner that allows for easy access to necessary medications, and there are regulations that govern this process.

Opened medications should not necessarily be disposed of at the end of each shift; they may be retained if they are still within their stability period and are properly stored according to protocols.

Cataracts are not a contraindication for cholinesterase inhibitors like neostigmine.

Hypertension is not a direct contraindication for cholinesterase inhibitor therapy, although caution may be exercised depending on the overall health status of the client.

Hypothyroidism is not contraindicated for cholinesterase inhibitors; however, it should be managed appropriately.

Furosemide is a diuretic that promotes urine production but is not indicated for treating bladder distention or urinary retention post-surgery.

Lorazepam is an anxiolytic medication and does not address urinary retention or bladder distention.

Atropine is an anticholinergic medication that can actually inhibit bladder contraction, making it inappropriate for this situation.

Sargramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF) used to stimulate the production of white blood cells but is not specifically indicated for anemia.

Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that increases white blood cell counts and is not used for treating anemia.

Romiplostim is a thrombopoietin receptor agonist used to treat thrombocytopenia (low platelet count) and is not indicated for anemia.

"Cloudy" is not a medication and does not address any adverse effects related to topotecan.

Insulin lispro is a rapid-acting insulin used to control blood sugar levels and does not relate to the adverse effects of topotecan.

Docusate sodium is a stool softener used to prevent constipation, but it does not specifically address the nausea and vomiting associated with chemotherapy.

Prednisone is a corticosteroid that may be used for other indications but is not primarily indicated for treating the nausea and vomiting caused by topotecan.

Hydrochlorothiazide does not prevent angiotensin II from binding with receptor sites; this action is typically associated with ACE inhibitors or angiotensin receptor blockers.

Hydrochlorothiazide does not block beta receptors; this is the mechanism of action for beta-blockers.

Hydrochlorothiazide does not promote the movement of extravascular fluids into the vascular compartment; instead, it reduces blood volume by promoting diuresis.